Rhumbline Advisers Clene Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$2.1 - $4.12 $35,529 - $69,706	-16,919 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.42 - $4.42 $4,755 - $8,685	1,965 Added 13.14%	16,919 $67,000
Q4 2021 Feb 10, 2022	SELL	$3.95 - $7.53 $2,429 - $4,630	-615 Reduced 3.95%	14,954 $61,000
Q3 2021 Nov 12, 2021	BUY	$6.83 - $13.58 $3,674 - $7,306	538 Added 3.58%	15,569 $106,000
Q2 2021 Aug 05, 2021	BUY	$6.98 - $13.33 $104,916 - $200,363	15,031 New	15,031 $169,000

7.44M

48.1K

160K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $21M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.